All In Biotech

Drug Trial Radar · NCT01150344

Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria

Effectiveness and Safety Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria : a Multicentric Study

Last checked: Nov 20, 2026Latest source record: Dec 9, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 317 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

317

Actual

Start

Jul 2010

Primary completion

Apr 2014

Study completion Nov 2015

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 24, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Riamet® or Malarone® are both recommended as the first line treatment for uncomplicated malaria in France, according to the French consensus Conference revised in 2007 on the treatment of imported malaria. The aim of the study is to compare both tolerance and efficacy of Malarone® and Riamet® in the treatment of uncomplicated imported malaria and to determine clinical and parasitological predictive factors associated with a less effectiveness. It's a multicentric, randomised study in adults with uncomplicated malaria. Treatment will be administered for 3 days, and patients will be followed for 28 days, to evaluate the therapeutic evolution. 640 patients will be included among 15 centres.

Conditions

  • Malaria

Interventions

  • Malarone (atovaquone + proguanil combination)Drug

    4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.

  • RIAMET (artemether + LUMEFANTRIN combination)Drug

    4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of cases where a second line treatment is used for either intolerance or lack of effectivenessTime frame: within the 28 days after diagnosis of malaria

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hôpital Avicenne

    Bobigny, Seine St Denis, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.